Sarepta Therapeutics (NASDAQ:SRPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar pchop123 (76.57) Submitted: 1/4/2013 10:23:15 AM : Outperform Start Price: $28.50 SRPT Score: -9.02

worth another ride UP

Report this Post Reply

Featured Broker Partners


Advertisement